When was Functional Neuromodulation founded?

Functional Neuromodulation was founded in 2010.

Where is Functional Neuromodulation located?

Functional Neuromodulation is headquartered in Boston, United States.

Who is the current CEO of Functional Neuromodulation?

Vince Owens of Functional Neuromodulation.

How many employees does Functional Neuromodulation have?

As of Aug 31, 2026, the latest employee count at Functional Neuromodulation is 3.

Is Functional Neuromodulation a funded company?

Functional Neuromodulation is a funded company, having raised a total of $3M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of Functional Neuromodulation?

Functional Neuromodulation's latest funding was a $***** Seed round on Mar 13, 2012, with participation from 1 investor.

Where does Functional Neuromodulation rank among its competitors?

Functional Neuromodulation ranks 6th amongst 17 active competitors, of which 6 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Cognito Therapeutics, which secured $105M in Mar, 2026.

Who are the top competitors of Functional Neuromodulation?

Functional Neuromodulation's top competitors include Cognito Therapeutics, Grey Matter Neurosciences and NeuroEM. Among them, Cognito Therapeutics secured the most recent funding round in March, 2026.

Functional Neuromodulation - 2026 Company Profile, Team, Funding & Competitors

Functional Neuromodulation is a seed company based in Boston (United States), founded in 2010 by Andres Lozano. It operates as a Deep Brain Stimulation of the Fornix (DBSf) technology for Alzheimer's disease treatment. Functional Neuromodulation has raised $3M in funding from Southern New Hampshire Health. The company has 17 active competitors, including 6 that are funded. Its top competitors include companies like Cognito Therapeutics, Grey Matter Neurosciences and NeuroEM.

Company Details

Functional Neuromodulation develops technologies for Deep Brain Stimulation of the Fornix (DBSf) to treat patients with Alzheimer's disease. The fornix connects the hippocampus to other parts of the limbic system, and is a major inflow and output pathway in the brain’s memory circuit that is the first areas of the brain to be affected by Alzheimer's. DBS therapy is used for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease, chronic intractable primary dystonia, treatment of refractory epilepsy, and treatment-resistant obsessive-compulsive disorder. Functional NeuroModulation's investors include Genesys Capital, Foundation Medical Partners and Medtronic.

Key Metrics

Founded Year

2010

Location

Boston, United States

Stage

Seed

Total Funding

$3M in 2 rounds

Latest Funding Round

Seed, Mar 13, 2012, $*****

Investors

Southern New Hampshire Health & 4 more

Ranked

6^th among 17 active competitors

Employee Count

3 as on Aug 31, 2026

Similar Companies

Cognito Therapeutics & 17 more

View Functional Neuromodulation's full profile

Functional Neuromodulation has raised a total funding of $3M over 2 rounds. Its latest funding round was a Seed round on Mar 13, 2012 for $*****. 1 investor participated in its latest round. Functional Neuromodulation has 5 institutional investors.

Here is the list of recent funding rounds of Functional Neuromodulation:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 13, 2012	4018214	Seed	1218501	2843531	9098127	4347720

Access funding benchmarks and valuations. Sign up today!

View details of Functional Neuromodulation's funding rounds and investors

The founders of Functional Neuromodulation is Andres Lozano. Vince Owens is the CEO of Functional Neuromodulation.

Here are the details of Functional Neuromodulation's key team members:

Andres Lozano: Founder of Functional Neuromodulation.
Vince Owens: CEO of Functional Neuromodulation.

View details of Functional Neuromodulation's Founder profiles and Board Members

Functional Neuromodulation's employee count trend

Functional Neuromodulation has 3 employees as of Aug 26. Here is Functional Neuromodulation's employee count trend over the years:

Employee count trend for Functional Neuromodulation

Uncover Functional Neuromodulation's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Functional Neuromodulation include Cognito Therapeutics, Grey Matter Neurosciences and NeuroEM. Here is the list of Top 10 competitors of Functional Neuromodulation, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cognito Therapeutics 2016, Cambridge (United States), Series C	Developer of a medical device for the treatment of Alzheimer's disease	$420M	Morningside, FoundersX Ventures & 10 others	64/100
2nd	Grey Matter Neurosciences 2021, Toronto (Canada), Seed	Developer of medical devices for neurological disease treatment	$14M	Wittington Ventures, Ontario Centre of Innovation ... & 2 others	55/100
3rd	NeuroEM 2013, Tampa (United States), Series A	Developer of medical device a non-invasive treatment for cognitive decline	$9M	Bluelake, New York Angels & 1 others	50/100
4th	Sinaptica Therapeutics 2022, Cambridge (United States), Seed	Developer of personalized closed-loop neuromodulation therapy for Alzheimer’s Disease	-	Sony Innovation Fund, CABHI	45/100
5th	OptoCeutics 2018, Kongens Lyngby (Denmark), Seed	Provider of solutions for treating and diagnosing neurological disease	$2.63M	EIC Fund, Europa & 4 others	42/100
6th	Functional Neuromodulation 2010, Boston (United States), Seed	Deep Brain Stimulation of the Fornix (DBSf) technology for Alzheimer's disease treatment	$3M	Medtronic, Genesys Capital & 3 others	35/100
7th	Braingrade 2019, Wilmington (United States), Unfunded	Developer of a medical device for treatment of Alzheimer's	-	-	30/100
8th	The Brain Protection Company 2002, Paddington (Australia), Funding Raised	Developer of therapies and diagnostics solutions to manage dementia and Alzheimer’s diseases	-	Gates, M.H. Carnegie & Co	29/100
9th	YoTeCuido Alzheimer 2016, A Coruna (Spain), Unfunded	App-based platform provider for caregivers and Alzheimer's patients	-	-	26/100
10th	Lazaro Reus (Spain), Unfunded	Lazaro » Home	-	-	24/100